Medicis Announces FDA Approval of Broader Indication for Vanos
SCOTTSDALE, Ariz., March 2, 2006 -- Medicis today announced that the Food and Drug Administration ("FDA") has broadened the indication of Vanos, a Class I corticosteroid launched in April 2005 and originally indicated for the treatment of plaque-type psoriasis. Vanos is now indicated as a primary therapy for all inflammatory and pruritic skin conditions in patients 12 years of age or older which are responsive to corticosteroids. Such conditions include eczema and poison ivy, which occur commonly. The unique formulation of Vanos provides doctors and patients with the convenience of a super high potency vehicle in the form of a cream for once or twice daily application in psoriasis and once daily in the other indicated conditions. Vanos is patent protected until 2021.
Vanos is available by prescription in a 30-gram size and a 60-gram size. The most common adverse events associated with the use of Vanos are headache and burning at the application site. Vanos is contraindicated for use by patients with a history of hypersensitivity to its components.
When used as directed, Vanos is safe and efficacious for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Full prescribing information for Vanos can be obtained by contacting Medicis. Consult your physician to see if Vanos is right for you.
Posted: March 2006